Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/56510
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHanberger, Håkan-
dc.contributor.authorAntonelli, Massimo-
dc.contributor.authorHolmbom, Martin-
dc.contributor.authorLipman, Jeffrey-
dc.contributor.authorPickkers, Peter-
dc.contributor.authorLeone, Marc-
dc.contributor.authorRello, Jordi-
dc.contributor.authorSakr, Yasser-
dc.contributor.authorWalther, Sten M.-
dc.contributor.authorVanhems, Philippe-
dc.contributor.authorVincent, Jean-Louis-
dc.date.accessioned2020-05-21T10:32:15Z-
dc.date.available2020-05-21T10:32:15Z-
dc.date.issued2014-
dc.identifier.citationHanberger, H., Antonelli, M., Holmbom, M., Lipman, J., Pickkers, P., Leone, M., ... & Vincent, J. L. (2014). Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. BMC Infectious Diseases, 14(1), 1-9.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/56510-
dc.description.abstractBackground: Antimicrobial resistance is an increasing concern in ICUs worldwide. Infection with an antibiotic resistant (ABR) strain of an organism is associated with greater mortality than infection with the non-resistant strain, but there are few data assessing whether being admitted to an intensive care unit (ICU) with high levels of antimicrobial resistance is associated with a worse outcome than being admitted to an ICU with low rates of resistance. The aim of this study was, therefore, to compare the characteristics of infections and antibiotic treatments and patient outcomes in patients admitted to ICUs in countries considered as having high levels of antibiotic resistance and those admitted to ICUs in countries considered as having low levels of antibiotic resistance.Methods: Data from the large, international EPIC II one-day point prevalence study on infections in patients hospitalized in ICUs were used. For the current study, we compared the data obtained from patients from two groups of countries: countries with reported MRSA rates of ≥ 25% (highABR: Greece, Israel, Italy, Malta, Portugal, Spain, and Turkey) and countries with MRSA rates of < 5% (lowABR: Denmark, Finland, Netherlands, Norway, and Sweden).Results: On the study day, 1187/2204 (53.9%) patients in the HighABR ICUs were infected and 255/558 (45.7%) in the LowABR ICUs (P < 0.01). Patients in the HighABR ICUs were more severely ill than those in the LowABR ICUs, as reflected by a higher SAPS II score (35.6 vs 32.7, P < 0.05) and had longer median ICU (12 days vs 5 days) and hospital (24 days vs 16 days) lengths of stay. They also had higher crude ICU (20.0% vs 15.4%) and hospital (27.0% vs 21.5%) mortality rates (both P < 0.05). However, after multivariable adjustment and matched pair analysis there were no differences in ICU or hospital mortality rates between High or LowABR ICU patients overall or among those with infections.Conclusions: Being hospitalized in an ICU in a region with high levels of antimicrobial resistance is not associated per se with a worse outcome.en_GB
dc.language.isoenen_GB
dc.publisherBioMed Central Ltd.en_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectAntibioticsen_GB
dc.subjectInfectionen_GB
dc.subjectPolypeptidesen_GB
dc.subjectBeta lactam antibioticsen_GB
dc.subjectAntibiotics -- Therapeutic useen_GB
dc.subjectCritically ill -- Careen_GB
dc.subjectAminopeptidases -- Analysisen_GB
dc.subjectBacterial diseases -- Diagnosisen_GB
dc.titleInfections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levelsen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holderen_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.1186/1471-2334-14-513-
dc.publication.titleBMC Infectious Diseasesen_GB
Appears in Collections:Scholarly Works - ERCMedGen



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.